TOVX

Business Context and Reporting Period

Company: Sheffield Pharmaceuticals, Inc. (Note: Request metadata listed "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 1999
Status: Development stage enterprise focused on pulmonary drug delivery technologies (Metered Solution Inhaler and Aerosol Drug Delivery System).
Operations: The Company has generated minimal operating revenue and sustained significant net operating losses. It relies on strategic alliances (Elan, Zambon, Siemens) and external funding to continue operations.

Key Financial Metrics

Debt and Liquidity:

• Convertible Promissory Note: $1,500,000 outstanding (Elan facility).
• Note Payable (Related Party): $104,145 (due May 1999).
• Sponsored Research Payable: $449,805.
• Liquidity: Cash balance of $1.9 million as of March 31, 1999. Management states ability to meet obligations through December 1999 is dependent on obtaining additional funding.

Material Changes vs. Prior Period

• Revenue: Total revenue increased to $21,877 from $953 in Q1 1998, driven entirely by higher interest income ($21,877 vs. $953) due to increased cash balances. No sublicense revenue was generated in the quarter.
• Net Loss: Net loss improved significantly to $(1.16) million from $(2.26) million in Q1 1998.
• Research & Development (R&D): R&D expenses decreased by $954,062 to $654,979. This reduction is primarily due to the shifting of development responsibility for respiratory applications of the MSI to partner Zambon.
• General & Administrative (G&A): G&A expenses decreased by $112,827 to $499,663, attributed to lower compensation costs from a reduced employee count.
• Interest Expense: Decreased to $29,891 from $42,470 following the conversion of Series A Preferred Stock and Convertible Subordinated Debentures into Common Stock during 1998.

Outlook, Risks, and Management Commentary

Outlook and Capital Resources:

• The Company expects to incur additional costs for ongoing R&D, preclinical/clinical testing, and patent enforcement.
• Management believes it will require additional funds to meet future costs, to be obtained through equity/debt offerings or collaboration agreements.
• Commitments: Committed to fund an additional $1,729,000 for pulmonary delivery system development subsequent to March 31, 1999.
• Financing Facilities: $500,000 remaining available under the Elan convertible note. Zambon provided a $1 million interest-free advance in May 1999 (repayable 2002 or upon milestones).

Risks and Contingencies:

• Going Concern: The financial statements are prepared on a going concern basis, but there is no assurance the Company will generate sufficient revenue to be profitable or obtain necessary funding.
• Year 2000 Compliance: Estimated cost less than $25,000. Substantially all software is compliant; hardware upgrades expected by Q2 1999. Risks remain regarding third-party vendors (universities/labs).
• Commercialization: No assurance that technologies will be successfully commercialized or that revenues will fund operations.

Investor Verification Checklist

• Cash Runway: Verify if the $1.9 million cash balance is sufficient to cover the committed $1.73 million development funding plus ongoing operating losses through the end of 1999.
• Debt Maturity: Confirm the repayment status of the $104,145 related party note due May 1999.
• Partnership Reliance: Assess the risk exposure if partners (Zambon, Elan) fail to meet their funding or development obligations.
• Capital Raises: Monitor for announcements of new equity or debt offerings required to sustain operations beyond December 1999.
• Year 2000 Status: Verify completion of hardware upgrades and third-party compliance assessments by July 1999.